187 related articles for article (PubMed ID: 9760024)
21. Cannabinoid receptors and their endogenous agonist, anandamide.
Axelrod J; Felder CC
Neurochem Res; 1998 May; 23(5):575-81. PubMed ID: 9566594
[TBL] [Abstract][Full Text] [Related]
22. Changes in rat brain cannabinoid binding sites after acute or chronic exposure to their endogenous agonist, anandamide, or to delta 9-tetrahydrocannabinol.
Romero J; García L; Fernández-Ruiz JJ; Cebeira M; Ramos JA
Pharmacol Biochem Behav; 1995 Aug; 51(4):731-7. PubMed ID: 7675852
[TBL] [Abstract][Full Text] [Related]
23. A peripheral mechanism for CB1 cannabinoid receptor-dependent modulation of feeding.
Gómez R; Navarro M; Ferrer B; Trigo JM; Bilbao A; Del Arco I; Cippitelli A; Nava F; Piomelli D; Rodríguez de Fonseca F
J Neurosci; 2002 Nov; 22(21):9612-7. PubMed ID: 12417686
[TBL] [Abstract][Full Text] [Related]
24. Relative efficacies of cannabinoid CB1 receptor agonists in the mouse brain.
Burkey TH; Quock RM; Consroe P; Ehlert FJ; Hosohata Y; Roeske WR; Yamamura HI
Eur J Pharmacol; 1997 Oct; 336(2-3):295-8. PubMed ID: 9384246
[TBL] [Abstract][Full Text] [Related]
25. Cannabinomimetic behavioral effects of and adenylate cyclase inhibition by two new endogenous anandamides.
Barg J; Fride E; Hanus L; Levy R; Matus-Leibovitch N; Heldman E; Bayewitch M; Mechoulam R; Vogel Z
Eur J Pharmacol; 1995 Dec; 287(2):145-52. PubMed ID: 8749028
[TBL] [Abstract][Full Text] [Related]
26. Dual effects of anandamide on NMDA receptor-mediated responses and neurotransmission.
Hampson AJ; Bornheim LM; Scanziani M; Yost CS; Gray AT; Hansen BM; Leonoudakis DJ; Bickler PE
J Neurochem; 1998 Feb; 70(2):671-6. PubMed ID: 9453561
[TBL] [Abstract][Full Text] [Related]
27. Cannabimimetic fatty acid derivatives: the anandamide family and other endocannabinoids.
Di Marzo V; Bisogno T; De Petrocellis L; Melck D; Martin BR
Curr Med Chem; 1999 Aug; 6(8):721-44. PubMed ID: 10469888
[TBL] [Abstract][Full Text] [Related]
28. Highly selective CB(1) cannabinoid receptor ligands and novel CB(1)/VR(1) vanilloid receptor "hybrid" ligands.
Di Marzo V; Bisogno T; De Petrocellis L; Brandi I; Jefferson RG; Winckler RL; Davis JB; Dasse O; Mahadevan A; Razdan RK; Martin BR
Biochem Biophys Res Commun; 2001 Feb; 281(2):444-51. PubMed ID: 11181068
[TBL] [Abstract][Full Text] [Related]
29. Head group analogs of arachidonylethanolamide, the endogenous cannabinoid ligand.
Khanolkar AD; Abadji V; Lin S; Hill WA; Taha G; Abouzid K; Meng Z; Fan P; Makriyannis A
J Med Chem; 1996 Oct; 39(22):4515-9. PubMed ID: 8893848
[TBL] [Abstract][Full Text] [Related]
30. Inhibitory effects of cannabinoid receptor ligands on electrically-evoked responses in rat isolated tracheal ring segments.
Yousif MH; Oriowo MA
Pharmacol Res; 1999 Nov; 40(5):415-21. PubMed ID: 10527656
[TBL] [Abstract][Full Text] [Related]
31. Assessment of anandamide interaction with the cannabinoid brain receptor: SR 141716A antagonism studies in mice and autoradiographic analysis of receptor binding in rat brain.
Adams IB; Compton DR; Martin BR
J Pharmacol Exp Ther; 1998 Mar; 284(3):1209-17. PubMed ID: 9495885
[TBL] [Abstract][Full Text] [Related]
32. The pharmacological activity of anandamide, a putative endogenous cannabinoid, in mice.
Smith PB; Compton DR; Welch SP; Razdan RK; Mechoulam R; Martin BR
J Pharmacol Exp Ther; 1994 Jul; 270(1):219-27. PubMed ID: 8035318
[TBL] [Abstract][Full Text] [Related]
33. The preimplantation mouse embryo is a target for cannabinoid ligand-receptor signaling.
Paria BC; Das SK; Dey SK
Proc Natl Acad Sci U S A; 1995 Oct; 92(21):9460-4. PubMed ID: 7568154
[TBL] [Abstract][Full Text] [Related]
34. Inhibition of long-term potentiation in rat hippocampal slices by anandamide and WIN55212-2: reversal by SR141716 A, a selective antagonist of CB1 cannabinoid receptors.
Terranova JP; Michaud JC; Le Fur G; Soubrié P
Naunyn Schmiedebergs Arch Pharmacol; 1995 Nov; 352(5):576-9. PubMed ID: 8751088
[TBL] [Abstract][Full Text] [Related]
35. (R)-methanandamide, but not anandamide, substitutes for delta 9-THC in a drug-discrimination procedure.
Burkey RT; Nation JR
Exp Clin Psychopharmacol; 1997 Aug; 5(3):195-202. PubMed ID: 9260067
[TBL] [Abstract][Full Text] [Related]
36. Characterization of delta9-tetrahydrocannabinol and anandamide antinociception in nonarthritic and arthritic rats.
Smith FL; Fujimori K; Lowe J; Welch SP
Pharmacol Biochem Behav; 1998 May; 60(1):183-91. PubMed ID: 9610941
[TBL] [Abstract][Full Text] [Related]
37. Anandamide hydroxylation by brain lipoxygenase:metabolite structures and potencies at the cannabinoid receptor.
Hampson AJ; Hill WA; Zan-Phillips M; Makriyannis A; Leung E; Eglen RM; Bornheim LM
Biochim Biophys Acta; 1995 Nov; 1259(2):173-9. PubMed ID: 7488638
[TBL] [Abstract][Full Text] [Related]
38. Changes in rat brain energetic metabolism after exposure to anandamide or Delta(9)-tetrahydrocannabinol.
Costa B; Colleoni M
Eur J Pharmacol; 2000 Apr; 395(1):1-7. PubMed ID: 10781666
[TBL] [Abstract][Full Text] [Related]
39. Evidence for a new G protein-coupled cannabinoid receptor in mouse brain.
Breivogel CS; Griffin G; Di Marzo V; Martin BR
Mol Pharmacol; 2001 Jul; 60(1):155-63. PubMed ID: 11408610
[TBL] [Abstract][Full Text] [Related]
40. The cannabinoid CB1 receptor antagonist SR141716A attenuates the memory impairment produced by delta9-tetrahydrocannabinol or anandamide.
Mallet PE; Beninger RJ
Psychopharmacology (Berl); 1998 Nov; 140(1):11-9. PubMed ID: 9862397
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
